Home/Filings/4/0000899243-19-009015
4//SEC Filing

Joslyn Alan 4

Accession 0000899243-19-009015

CIK 0001174940other

Filed

Mar 26, 8:00 PM ET

Accepted

Mar 27, 4:05 PM ET

Size

9.4 KB

Accession

0000899243-19-009015

Insider Transaction Report

Form 4
Period: 2019-03-25
Joslyn Alan
DirectorCEO and President
Transactions
  • Purchase

    Series 2 Common Stock Warrants (right to buy)

    2019-03-25+33,33350,000 total
    Exercise: $0.90From: 2019-03-25Exp: 2024-03-25Common Stock (33,333 underlying)
  • Purchase

    Common Stock

    2019-03-25+66,66766,667 total
  • Purchase

    Series 1 Common Stock Warrants (right to buy)

    2019-03-25+33,33350,000 total
    Exercise: $0.75From: 2019-03-25Exp: 2020-09-25Common Stock (33,333 underlying)
Footnotes (1)
  • [F1]Purchase of Units consisting of one share of common stock and Series 1 Warrant to purchase one-half of a share of our Common Stock (exercisable through the earlier of 20 days post read out of AG013 clinical trial data or eighteen months) and a Series 2 Warrant to purchase one-half of a share of our Common Stock in an underwritten public offering at the price of $0.75 per Unit, which was the price paid by the public for such Units.

Issuer

ORAGENICS INC

CIK 0001174940

Entity typeother

Related Parties

1
  • filerCIK 0001294887

Filing Metadata

Form type
4
Filed
Mar 26, 8:00 PM ET
Accepted
Mar 27, 4:05 PM ET
Size
9.4 KB